Polymyalgia rheumatica shows metabolomic alterations that are further altered by glucocorticoid treatment: Identification of metabolic correlates of fatigue.
Manning JE. et al, (2024), J autoimmun, 147
Vasculitic neuropathy-related disability, pain, quality of life, and autonomic symptoms: A survey of 312 patients.
Collins MP. et al, (2024), Rheumatology (oxford)
2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis
Ponte C. et al, (2022), Arthritis & rheumatology, 74, 1881 - 1889
2022 American College of Rheumatology/EULAR Classification Criteria for Takayasu Arteritis.
Grayson PC. et al, (2022), Arthritis rheumatol, 74, 1872 - 1880
2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis.
Ponte C. et al, (2022), Arthritis rheumatol, 74, 1881 - 1889
2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis.
Ponte C. et al, (2022), Ann rheum dis, 81, 1647 - 1653
2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis.
Grayson PC. et al, (2022), Ann rheum dis, 81, 1654 - 1660
2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis
Grayson PC. et al, (2022), Arthritis and rheumatology
Experience from the first UK inter-regional specialist multidisciplinary meeting in the diagnosis and management of IgG4-related disease.
Goodchild G. et al, (2020), Clin med (lond), 20, e32 - e39
Early development of new cardiovascular risk factors in the systemic vasculitides.
Monti S. et al, (2020), Clin exp rheumatol, 38 Suppl 124, 126 - 134
2018 Update of the EULAR recommendations for the management of large vessel vasculitis.
Hellmich B. et al, (2020), Ann rheum dis, 79, 19 - 30
Peripheral neuropathy in antineutrophil cytoplasmic antibody-associated vasculitides: Insights from the DCVAS study.
Bischof A. et al, (2019), Neurol neuroimmunol neuroinflamm, 6
Identification of Novel Adenosine Deaminase 2 Gene Variants and Varied Clinical Phenotype in Pediatric Vasculitis.
Gibson KM. et al, (2019), Arthritis rheumatol, 71, 1747 - 1755
Patterns of Arterial Disease in Takayasu's Arteritis and Giant Cell Arteritis.
Gribbons KB. et al, (2019), Arthritis care res (hoboken)
Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis.
Tomasson G. et al, (2019), J rheumatol, 46, 928 - 934
Giant cell arteritis: new concepts, treatments and the unmet need that remains.
Coath F. et al, (2019), Rheumatology (oxford), 58, 1123 - 1125
Giant cell arteritis: new concepts, treatments and the unmet need that remains.
Coath F. et al, (2019), Rheumatology (oxford), 58
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SIRUKUMAB IN THE TREATMENT OF PATIENTS WITH GIANT CELL ARTERITIS
Schmidt W. et al, (2019), Annals of the rheumatic diseases, 78, 827 - 827
Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D. et al, (2019), Arthritis rheumatol, 71, 952 - 963
HOW TO ASSESS PATIENT WITH SUSPECTED VASCULITIS
Luqmani R., (2019), Annals of the rheumatic diseases, 78, 36 - 37